Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study

  • Michael Rainer
  • A. Wuschitz
  • C. Jagsch
  • C. Erb
  • J.-J. Chirikdjian
  • H. A. M. Mucke
Dementias - Short Communication

Abstract

Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer’s disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this ‘real-life’ setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.

Keywords

Alzheimer’s disease Dementia Memantine Activities of daily living Post-marketing ‘Real-life’ setting 

References

  1. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22(3):209–221PubMedCrossRefGoogle Scholar
  2. Bakchine S, Loft H (2007) Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 11:471–479PubMedGoogle Scholar
  3. Calabrese P, Essner U, Förstl H (2007) Memantine (Ebixa®) in clinical practice–results of an observational study. Dement Geriatr Cogn Disord 24:111–117PubMedCrossRefGoogle Scholar
  4. Doody R, Wirth Y, Schmitt F, Möbius HJ (2004) Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 18(2):227–232PubMedCrossRefGoogle Scholar
  5. Ferris S, Ihl R, Robert P et al (2009) Treatment effects of Memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement 5(5):369–374PubMedCrossRefGoogle Scholar
  6. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12:189–198PubMedCrossRefGoogle Scholar
  7. Gauthier S, Wirth Y, Möbius HJ (2005) Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 20(5):459–464PubMedCrossRefGoogle Scholar
  8. Georges J, Jansen S, Jackson J et al (2008) Alzheimer’s disease in real life–the dementia carer’s survey. Int J Geriatr Psychiatry 23:546–551PubMedCrossRefGoogle Scholar
  9. Herrmann N, Gauthier S (2008) Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 179:1279–1287PubMedCrossRefGoogle Scholar
  10. Hofbauer RK, Saxton J, Woodward M et al (2009) Effects of memantine on functional communication in patients with moderate AD: results of a 12-week placebo-controlled trial. Alzheimers Dement 5(4):256–257CrossRefGoogle Scholar
  11. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91–104Google Scholar
  12. Lopez OL, Becker JT, Wahed AS et al (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80(6):600–607PubMedCrossRefGoogle Scholar
  13. McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMedGoogle Scholar
  14. Mecocci P, Bladstrom A, Stender K (2009) Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 24(5):532–538PubMedCrossRefGoogle Scholar
  15. Merz Pharmaceuticals GmbH (August 2007) Axura® Tablets. Summary of Product Characteristics (SPC)Google Scholar
  16. National Institute for Mental Health (1976) 028 CGI: clinical global impressions. In: Guy W (ed) ECDEU assessment manual for psychopharmacology. Rockville, USAGoogle Scholar
  17. Peskind ER, Potkin SG, Pomara N et al (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704–715PubMedCrossRefGoogle Scholar
  18. Porsteinsson AP, Grossberg GT, Mintzer J et al (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83–89PubMedCrossRefGoogle Scholar
  19. Reisberg B, Schneider L, Doody R et al (1997) Clinical global measures of dementia Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 11(Suppl 3):S8–S18Google Scholar
  20. Reisberg B, Doody R, Stöffler A et al (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348:1333–1341PubMedCrossRefGoogle Scholar
  21. Suh GH, Ju YS, Yeon BK, Shah A (2004) A longitudinal study of Alzheimer’s disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 19(9):817–824PubMedCrossRefGoogle Scholar
  22. Tariot PN, Farlow MR, Grossberg GT et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA 291:317–324PubMedCrossRefGoogle Scholar
  23. van Dyck CH, Tariot PN, Meyers B, Resnick ME, MemantineMEM-MD-01 Study Group (2007) A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 21:136–143PubMedCrossRefGoogle Scholar
  24. Wilkinson D, Andersen HF (2007) Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 24:138–145PubMedCrossRefGoogle Scholar
  25. Winblad B, Jones RW, Wirth Y et al (2007) Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24:20–27PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Michael Rainer
    • 1
  • A. Wuschitz
    • 2
  • C. Jagsch
    • 3
  • C. Erb
    • 4
  • J.-J. Chirikdjian
    • 5
  • H. A. M. Mucke
    • 6
  1. 1.Memory Clinic and Psychiatric DepartmentDonauspital Sozialmedizinisches Zentrum OstWienAustria
  2. 2.Practice for Psychiatry and NeurologyWienAustria
  3. 3.Psychiatric Hospital WelsWelsAustria
  4. 4.Merz PharmaceuticalsFrankfurt/MainGermany
  5. 5.Zak Pharma GmbHWienAustria
  6. 6.H. M. Pharma ConsultancyWienAustria

Personalised recommendations